

INDEX

A

- Absorptiometry, dual-energy X-ray, 94–95
- Acetaminophen, 30
- Acetaminophen overdose, 47
- Acne, 38–39
- Acrodermatitis enteropathica, 253
- Adam's forward bend test, 56
- Adderall XR, 41
- Adolescent medicine, 40–41
- Allergen-specific immunotherapy/
 hyposensitization, in atopic dermatitis,
 264
- Allergic diseases, human milk and, 282–286
- Amino acids, common modifications of,
 23–24
- Amoxicillin, 32, 33
- Anabolic agents, in osteoporosis, 104
- Anemia, iron-deficiency, in homeless
 children, 180–181
- Anesthetics, transfer through human milk,
 46–47
- Angiotensin-converting enzyme inhibitors, 46
- Anorexia nervosa, reduced bone mass and,
 93–94
- Antibacterials, dental caries and, 231
- Antibiotics, adverse effects of, 47
 in atopic dermatitis, 262
- Antibody arrays, in basic research, 18–19
 in biomarker validation process, 19–20
 in clinical research, 19
- Antidepressants, 42
- Antihistamines, in atopic dermatitis, 262
- Apophysis, iliac, depiction of, 60
- Aristotle Complexity Score, 74–81
 and risk dependence on performance,
 74–75
 complexity based on indices calculated
 on observed data, 80–81
 complexity based on subjective
 probability and, 76–77

- future developments on data in, 81
 limitations of, 79
 technical difficulty and, 75–76
 two principles of, 77–79
 validation of, 80
- Asthma, in homeless children, 179–180
 inhaled corticosteroids versus
 montelukast in, 35
 long-acting beta-agonists in, 36
 prevention of, 35
- Atomoxetine, 41
- Attention-deficit hyperactivity disorder
 (ADHD), 41
- Autoantibodies, and autoimmune diseases, in
 human milk, 284
 in human milk, protection by, 285–286
- Autoimmune diseases, and autoantibodies, in
 human milk, 284
-
- ### B
- Best Pharmaceuticals for Children Act
 (BPCA), 29
- Beta agonists, long-acting, in asthma, 36
- Bisphosphonate therapy, in osteoporosis,
 98–100
 adverse effects of, 103–104
 monitoring of, 104, 105
 protocols for, 100–103
- Bone density, measurements of, 95
- Bone health, evaluation of, 94–96
- Bone mass, activity intervention effects on, 90
 ethnic differences in, 87, 88
 extrinsic factors and, 87, 89
 factors affecting accrual of, 86
 in men and women, compared, 86–87
 intrinsic and extrinsic factors associated
 with, 86
 low, evaluation of pediatric patients
 with, 97–98
- Bone metabolism markers, 98, 99
- Bone mineralization, and histology of rickets,
 120
- Breastfeeding, benefits and risks of, 275–304

Note: Page numbers of article titles are in **boldface** type.

Breastfeeding (*continued*)

- clinical application of information on, 292–293
- evolution of, 295–296
- decision-making by mothers and, 296
- deficiencies of micronutrients in human milk and, 279–282
- economic advantages of, 297
- insufficient milk transfer in, 278–279
- long-term preventative effects of, 277
- national and international support of, 296–297
- resolution of lactation problems in, 279
- risks associated with, 277–295
- superior health outcomes of infants and, 276–277

Bronchopulmonary dysplasia, 43

C

- Caffeine, for apnea of prematurity, 43
- Calcitriol, 118–119
- Calcium, and vitamin D, guidelines for intake of, 89
 - perinatal physiology of, 124
- Cardiology, 37–38
- Cephalosporins, 32–33
- Children's Health Fund (CHF), studies of homeless children, 177–183
- Cholera, 34
- Ciprofloxacin, 34
- Clonidine overdose, 47–48
- Coal tar preparations, in atopic dermatitis, 262
- Cold, treatment of, 31–32
- Computed tomography, peripheral quantitative, 96
 - quantitative, 95–96
- Congenital heart surgery. *See Heart surgery, congenital.*
- Congenital malformations, drugs and, 46
- Contraception, emergency, 40–41
- Contraceptives, 40
- Corticosteroids, 31–32
 - in Kawasaki syndrome, 38
 - inhaled, in asthma, 35
 - topical, in atopic dermatitis, 258
- Cough, treatment of, 31–32
- Group, 31
- Cushing syndrome, 92
- Cytokines, and chemokines, in human milk, 284
- Cytomegaloviruses, in human milk, 286

D

- Dental caries, acquisition and transmission of, 219–220
 - antibacterials in, 231
 - as common chronic disease of childhood, **215–239**
 - dental home and, 233–234
 - diet and nutrition and, 224–225
 - epidemiology of, 216–218
 - fluoride and, 229–231
 - microbiology of, 220–221
 - oral hygiene and, 225–229
 - pathology of, 218–219
 - prevention of, 221–234
 - probiotics and, 232–233
 - race and ethnicity and, 217
 - risk assessment tool (American Academy of Pediatric Dentistry), 224, 226–228
 - risk factors for, 223, 224
 - socioeconomic status and, 217–218
 - surgical treatment in, 233
 - taxonomy associated with, 215–216
 - xylitol and, 232
- Dental plaque, 220–221
- Depression, 42
- Dermatitis, atopic, 38, **241–273**
 - aeroallergens and, 244
 - alternative/complimentary therapies in, 264
 - antibiotics in, 262
 - antihistamines in, 262
 - assessment of severity of, 247–252
 - clinical manifestations of, 245–246
 - coal tar preparations in, 262
 - complications of, 253–254
 - diagnosis of, 246–247
 - diagnostic testing in, 254–255
 - differential diagnosis of, 252–253
 - epidemiology of, 242
 - food allergy and, 243–244
 - genetic predisposition to, 242
 - immunopathology of, 245
 - management of, 255–264
 - montelukast in, 264
 - pathogenesis and etiology of, 242–245
 - patient education in, 256
 - phototherapy in, 263
 - prevalence of, 241
 - probiotics and prebiotics in, 263–264
 - prognosis in, 265
 - psychosocial impact of, 247, 251–252
 - skin care in, 257–258
 - systemic immunosuppressants in, 258–259

- topical corticosteroids in, 258
 - topical immunomodulators in, 259–262
 - triggering factors in, 256–257
 - wet-wrap therapy in, 263
 - contact, 253
 - Dermatology, 38–39
 - Dexamethasone, 32
 - Dexrazoxane, 37
 - Dextromethorphan, 31
 - Diarrhea, infectious, 34
 - treatment of, 32
 - Diphtheria toxoids, 135, 139, 141
 - Disasters. See *Megadisasters*.
 - Doxorubicin, 37
 - Drugs, effects on lactation, 289–290
 - pediatric labeling information on, 29
 - transfer between mothers and infants, 45–48
-
- E**
- Eczema, nummular, 253
 - Endocrine disorders, 91–93
 - Erlotinib, 23
 - Erythromycin, 34
 - European Association of Cardio-Thoracic Surgery (EACTS), evaluation of quality of practice and, 67, 68, 71–74
-
- F**
- Fatty acids, in human milk, 284
 - Fever, fear of, 30–31
 - Fluoride, dental caries and, 229–231
 - Fluoxetine, 42
 - Food allergens, in human milk, 283–284
 - Fracture risk, evaluation of, in pediatric patients, 96
 - Fucosyloligosaccharides, in human milk, 291
-
- G**
- Galactosemia, breastfeeding and, 291–292
 - Gastrointestinal disease, 91
 - Gefitinib, 23
 - Gel electrophoresis, two-dimensional, 14–15
 - Gene product, alternative splicing of, 23
 - Glucocorticoid use, chronic, osteoporosis in, 102–103
 - Glycosylation, 23
 - Graft versus host disease, breastfeeding and, 292

- Growth hormone/insulin-like growth factor,
 - in osteoporosis, 105
- Guillain-Barré syndrome, 144
- Gynecology, 40–41

H

- Heart diseases network, multisocietal
 - congenital, 73–74
 - Heart surgery, congenital, Aristotle
 - complexity score and, 67–83
 - comparing outcomes between surgeons and centers, 74
 - cost of, 71
 - data collection system for, 72
 - data verification process and, 72–73
 - international nomenclature in, 72
 - long-term functional results of, 71
 - operative morbidity and, 69–71
 - operative mortality and, 68–69
 - quality care in, evaluation of, 67–83
 - satisfaction with, 71
 - Hepatitis A vaccine, 154, 155
 - Hepatitis C, 34–35
 - Hepatitis viruses, in human milk, 286
 - Homeless children, health care for, 177
 - health of, 173–187
 - studies of, 177–183
 - Homeless family, profile of, 174–175
 - Homelessness, and child health, 175–177
 - family, incidence of, 173–174
 - Human immunodeficiency virus type I, in human milk, 287–289, 293–294
 - Human papilloma virus vaccine,
 - prophylactic, 147
 - quadrivalent, 144–148
 - Hydrocortisone, 44
 - Hypertension, 37
 - Hypotension, 44
 - Hypotonia, bone density in, 103
 - Hypovitaminosis D, and rickets, in older children and adolescents, 126
 - shedding light on, 115–134
-
- I**
- Ibuprofen, 30
 - IL-10, in human milk, 291
 - Immunization, schedule for, 136, 137
 - recent changes in, 152–157
 - status of homeless children, 178–179
 - update on, 135–171

Immunomodulators, topical, in atopic dermatitis, 259–262

Immunosuppressants, systemic, in atopic dermatitis, 258–259

Implanon, 40

Industrial pollutants, in human milk, 290

Infection(s), neonatal, 44
urinary tract, 34

Infectious agents, in human milk, 286–291

Infectious diseases, 32–35

Influenza vaccine, 155–157

Iron, bioavailability in human milk, 281

Isotretinoin, 38–39

K

Kawasaki syndrome, 37–38

L

Lactation, effects of drugs on, 289–290
vitamin D and, 124–125

Lactose and glucose, genetics defects in,
breastfeeding and, 291

Laryngotracheobronchitis, acute, 31

Leukemias, treatment of, 37

Levonorgestrel, 40

Liquid chromatography-tandem mass
spectrometry, 16–18

Lymphomas, treatment of, 37

M

Malnutrition, reduced bone mass and, 93–94

Megadisasters, barriers to preparedness for,
192
child reactions to, 202–206
children and, **189–214**
children with special health needs and,
198–199
critical response and recovery issues in,
191–209
decision-making in, 194–195
evacuation in, 191–195, 196
mental health needs after, guidelines for,
208
unmet, 206
mental health response to, 200–209
obtaining shelter in, 196–198
specialized equipment and care in,
199–200

Meningococcal conjugate vaccine, tetravalent,
141–144

Mental health, in homeless children, 181–183

Metformin, 39–40

Micronutrients, in human milk, deficiencies in,
breastfeeding and, 279–282

Migraines, 36–37

Milk, human, and allergic diseases, 282–286
composition of, evolution and,
275–276
defense agents in, 290–291
deficiencies in micronutrients in,
breastfeeding and, 279–282
feeding of, genetic diseases of
infancy and, 291–292
food allergens in, 283–284
for premature infants, 296
infectious agents in, 286–291
pesticides and industrial pollutants
in, 290

Montelukast, in asthma, 35
in atopic dermatitis, 264

Mumps, measles, rubella, and varicella
vaccine, 153–154

N

Natural disasters, children and, 189–190

Necrotizing enterocolitis, 45

Neonatology, medication use and, 43

Neurology, 36

New York Children's Health Project
(NYCHP), studies of homeless children,
177–183

Nonambulatory patients, bone density in, 103

Nutritional problems, of homeless children,
175–176

O

Obesity, new therapies for, 39

Oncology, 37

Oral health, 215
role of pediatricians in, 234–235

Osteogenesis imperfecta, 91, 92, 101–102

Osteoporosis, anabolic agents in, 104
and organ transplants, 93
bone calcium deposition patterns and,
86
diagnosis and treatment of, advances in,
85–114
diagnostic criteria for, 99
pediatric-specific background of, 85–86
treatment of, 98

Otitis externa, 33

Otitis media, acute, 33
in homeless children, 179

Overweight and obesity, in homeless
children, 181

P

- Pain, neonatal, 44–45
- Pamidronate, 101
- Parathyroid hormone, 93
in osteoporosis, 106–107
- Pediatric research and practice, proteomics in, 9–28
- Pediatric Research Equity Act (PREA), 29
- Pediatricians, role in oral health, 234–235
- Penicillin, 32
- Pentavalent combination vaccine, 157–158
- Pertussis vaccine, 135–141
- Pervasive developmental disorder (PDD), 42–43
- Pesticides, in human milk, 290
- Pharmacology, therapeutics, and toxicology, advances in, 29–53
- Pharyngitis, 32
streptococcal, 32–33
- Phenylketonuria, breastfeeding and, 292
- Phosphorylation, 23
- Phototherapy, in atopic dermatitis, 263
- Pimecrolimus, in atopic dermatitis, 260–262
- Pneumococcal conjugate vaccines, heptavalent, 158–160
- Pneumonia, 33–34
- Polycystic ovary syndrome, 39–40
- Polysaccharide vaccine, quadrivalent, 142
- Polyunsaturated fatty acids, in human milk, 281–282
- Posttraumatic stress reactions, following megadisasters, 201
- Prebiotics, and probiotics, in atopic dermatitis, 263–264
- Preterm infants, hypocalcemia in, 125–126
- Probiotics, and prebiotics, in atopic dermatitis, 263–264
dental caries and, 232–233
dental home and, 233–234
surgical treatment in, 233
- Proopiomelanocortin, 22
- Protein(s), detection of, arrays and, 18
four isoforms of, amino acids and, 17
modifications of, and disease, 23–24
secreted, enzymatic cleavage of single gene product and, 21–23
- Protein microarrays, 12
- Protein profiling strategies, 13–14

- Proteome, post-translational events and complexity of, 21–24
proteomics and, 10
- Proteomic methods, existing, limitations of, 20–21
- Proteomics, applications of protein biomarkers determined through, 10–11
clinical, three phase approach to, 11
clinical medicine and, 10–12
definition of, 9
in pediatric research and practice, 9–28
methods of, 12–20
paradigms in, 12–20
proteome and, 10
- Psoriasis, 252
- Psychiatry, 41–43
- Pulmonary problems, 35–36

R

- Rheumatoid arthritis, and lactation, 284
- Rickets, and hypovitaminosis D, in older children and adolescents, 126
shedding light on, 115–134
biochemical changes in, 122–123
childhood, calcium deficiency in, 126–127
clinical presentation of, by age, 120–122
histology of, bone mineralization and, 120
nutritional, treatment of, 128–129
roentgenographic diagnosis of, 123–124
- Risperidone, 42–43
- Rotavirus vaccine, monovalent human, 151–152
pentavalent (human-bovine) reassortant, 148
- Rubella virus, in human milk, 287

S

- Scabies, 253
- Scoliometer, 56–57
- Scoliosis, adolescent idiopathic, 59–61
detection of, 55–57
idiopathic, advances in, in children and adolescents, 55–66
etiology of, 55
types of, 57–59
infantile, 57
juvenile, 57–59
normal juvenile, 60, 61
surgical correction of, advances in, 61–64
- Seizures, 36
- Selective serotonin reuptake inhibitors, 45–46

Shelters, emergency, homelessness and, 174
 Society of Thoracic Surgeons (STS),
 evaluation of quality of practice and, 67,
 68, 71–74
 Sore throat, 32
 Spinal fusion, surgical, in adolescent scoliosis, 61
 Spinal orthosis, thoraco-lumbar, 59
 St. Geme, Joseph W., MD, 3–8
 Streptococcal pharyngitis, 32–33
 Strontium, in osteoporosis, 106
 Symptomatic care, 30–32
 Systemic lupus erythematosus, and lactation,
 285

T

T-cell leukemia virus type I, in human milk,
 287
 Tacrolimus, in atopic dermatitis, 259–262
 Terbinafine, 34
 Terrorism, children and, 190
 Tetanus vaccine, 135, 138, 139, 141
 TGF- β 1, in human milk, 290–291
 Tinea capitis, 34
 Tooth decay, 216
 Toxicology, 45–48

U

Ultrasound, quantitative, 96
 Urinary tract infection, 34

V

Vaccines, for adolescents, 135–148
 new, for children, 148–152
 Varicella vaccine, 152–153
 Vitamin B12 deficiency, 281
 Vitamin D, and calcium, perinatal physiology
 of, 124
 and lactation, 124–125
 deficiency of, prevention of, 127–128
 dietary sources of, 116, 118
 in human milk, 280
 metabolism of, biochemistry of,
 116–120
 roles of, 130
 Vitamin K, in human milk, 280
 Vomiting, treatment of, 32

W

Wet-wrap therapy, in atopic dermatitis, 263

X

Xenobiotics, breastfeeding and, 294
 Xerosis, in atopic dermatitis, 246
 Xylitol, dental caries and, 232

Z

Zinc deficiency, 281
 Zoledronic acid, 100